Clinical Implementation of Precision Medicine in Gastric Cancer
- Author:
Jaewook JEON
1
;
Jae Ho CHEONG
Author Information
- Publication Type:Review
- Keywords: Stomach neoplasm; Precision medicine; Tumor biomarkers; Adjuvant chemotherapy; Molecular targeted therapy
- MeSH: Biomarkers, Tumor; Chemotherapy, Adjuvant; Classification; Decision Making; Drug Therapy; Heterografts; Humans; Molecular Targeted Therapy; Organoids; Precision Medicine; Prognosis; Real-Time Polymerase Chain Reaction; RNA; Stomach Neoplasms
- From:Journal of Gastric Cancer 2019;19(3):235-253
- CountryRepublic of Korea
- Language:English
- Abstract: Gastric cancer (GC) is one of the deadliest malignancies in the world. Currently, clinical treatment decisions are mostly made based on the extent of the tumor and its anatomy, such as tumor-node-metastasis staging. Recent advances in genome-wide molecular technology have enabled delineation of the molecular characteristics of GC. Based on this, efforts have been made to classify GC into molecular subtypes with distinct prognosis and therapeutic response. Simplified algorithms based on protein and RNA expressions have been proposed to reproduce the GC classification in the clinical field. Furthermore, a recent study established a single patient classifier (SPC) predicting the prognosis and chemotherapy response of resectable GC patients based on a 4-gene real-time polymerase chain reaction assay. GC patient stratification according to SPC will enable personalized therapeutic strategies in adjuvant settings. At the same time, patient-derived xenografts and patient-derived organoids are now emerging as novel preclinical models for the treatment of GC. These models recapitulate the complex features of the primary tumor, which is expected to facilitate both drug development and clinical therapeutic decision making. An integrated approach applying molecular patient stratification and patient-derived models in the clinical realm is considered a turning point in precision medicine in GC.
